Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 6/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 4/20 | 1.00 |
| ▸ | MYLK | Q15746 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| K-252A SCHEMBL29434956 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13993461 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL31181849 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13485248 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL15575821 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL24112155 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13787898 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL968886 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL32665760 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL29660621 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735586-A1 | CELLULAR REPROGRAMMING | Samuel, Amy Jane (NZ) | 2026-05-06 | — | — | EP | claimed |
| EP-4713433-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | Children's Hospital Medical Center (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4709377-A2 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | Neuron23, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4680973-A1 | PROTEOMIC RISK SCORE FOR OSTEOARTHRITIS (OA) | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | NEURON23 INC (US) | 2026-01-08 | — | — | US | claimed |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | SMARTDYELIVERY GMBH (DE) | 2025-11-18 | — | — | US | claimed |
| EP-4633630-A1 | TREATMENT OF CANCER RESISTANT TO EGFR TKI USING C-MET INHIBITOR | Apollomics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250268913-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING | SMARTDYELIVERY GMBH (DE) | 2025-08-28 | — | — | US | claimed |
| WO-2025120106-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AN AVIAN EMBRYO CELLS | SUPRÊME (FR) | 2025-06-12 | — | — | WO | claimed |
| WO-2022226168-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | APOLLOMICS INC. (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| CN-110468051-B | K252A fermentation medium and preparation method thereof | 海正药业(杭州)有限公司 | 2022-08-23 | — | — | CN | claimed |
| US-20220249509-A1 | METHOD FOR PREVENTING HAIR LOSS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-11 | — | — | US | claimed |
| US-20220252603-A1 | METHOD FOR TREATING CANCER PATIENTS USING C-MET INHIBITOR | APOLLOMICS INC. (HANGZHOU) (CN) | 2022-08-11 | — | — | US | claimed |
| US-11390922-B2 | C-CBL mutations and uses thereof | UNIVERSITY OF CHICAGO (US) | 2022-07-19 | — | — | US | claimed |
| CN-114599978-A | Methods of treating cancer patients using C-MET inhibitors | 浙江冠科美博生物科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-3993764-A1 | METHOD FOR PREVENTING HAIR LOSS | Icahn School of Medicine at Mount Sinai (US) | 2022-05-11 | — | — | EP | claimed |
| WO-2022093685-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2 | NEURON23, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| EP-3980783-A1 | METHOD FOR TREATING CANCER PATIENTS USING C-MET INHIBITOR | Apollomics Inc. (Hangzhou) (CN) | 2022-04-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260011407-A1 | PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE | LRRK2, PARK7, BMP2K | NTRK1 202/4885PRKCQ 831/4885KDR 1874/4885 |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | PRKCH, PRKCZ, PIKFYVE | NTRK1 4490/4885PRKCQ 7/4885KDR 680/4885 |
| US-20220249509-A1 | METHOD FOR PREVENTING HAIR LOSS | MYLK3, MYLK4, MYLK | NTRK1 2344/4885PRKCQ 716/4885KDR 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.